There are 3397 resources available
LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
Presenter: Xiaohua Wu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Webcast
LBA105 - Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy
Presenter: Andrea Necchi
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 743MO, 744MO and LBA44
Presenter: Alexandra Leary
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
Q&A and Discussion
Presenter: All Speakers
Session: ESMO Clinical Practice Guidelines 1
Resources:
Slides
Webcast
LBA45 - Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
Presenter: Joyce Liu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA104 and LBA105
Presenter: Joost Boormans
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
746MO - Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)
Presenter: Jung-Min Lee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
Presenter: Martin Voss
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1884MO - Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
Presenter: Roberto Iacovelli
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast